Liver fibrosis screening, evaluation pathway, and management in patients with fatty liver
10.3760/cma.j.cn501113-20230807-00036
- VernacularTitle:非酒精性脂肪性肝病患者肝纤维化筛查、评估路径及管理
- Author:
Liang XU
1
;
Yuqiang MI
Author Information
1. 天津市第二人民医院肝病三科与脂肪肝中心 天津市肝病医学研究所，天津 300192
- Keywords:
Fatty liver;
Fibrosis;
Noninvasive;
Algorithm;
Management
- From:
Chinese Journal of Hepatology
2023;31(8):798-804
- CountryChina
- Language:Chinese
-
Abstract:
Non-alcoholic fatty liver disease (NAFLD) is not a benign condition, especially in patients with non-alcoholic steatohepatitis (NASH) combined with liver fibrosis grades F2-4, who have a higher risk of liver-related events and mortality. Thus, this population is considered "at-risk" for developing NASH. China has a large NAFLD patient population, so how to screen for those with liver fibrosis is an important socio-economic concern. At the moment, serological models, liver stiffness detection based on vibration-controlled transient elastography, and magnetic resonance elastography (MRE) are the only non-invasive tests (NITs) for liver fibrosis. The prevention and treatment guidelines for NAFLD at home and abroad are reviewed here, based on the research progress of NITs in recent years, so as to suggest screening, evaluation pathways, and management for liver fibrosis in patients with NAFLD.
